X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Global Pharma: Consolidation imminent... - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Oct 26, 2002

    Global Pharma: Consolidation imminent...

    The drop in market capitalization of pharma companies on the US bourses, gives one a clear indication of the unprecedented pressure on MNC pharma companies to sustain growth. The issues, which are giving a nightmare to these companies are wide ranging including patent expiration and dearth of new products.

    Further, intense competition from generic companies, especially from emerging countries like India is adding to the problems. The most immediate problem for these companies is the falling productiveness from their research labs. Despite a surge in R&D budgets, the number of new products coming out of research pipelines is getting squeezed. For an industry that attributes its high prices to the need to reinvest in R&D and boosting success ratio in research, productiveness becomes paramount. And judging by numbers, the days of price premiums seem poised to ebb out. Studies on R&D productivity show that a large portion of the R&D budget is absorbed into the clinical trials, which is the last stage of drug development. Ten years ago, for safety and efficacy 1,000 patients were enough. But now regulators are stressing on higher number of clinical trials to be done before a drug could be approved. This is not only increasing R&D budgets but also increasing the time to market for new drug discoveries, leaving a short period for them to cash in through patent exclusivity. The industry desperately is in need of a wonder drug, which just does not seem to be coming out from their pipelines.

    While on one hand, the R&D / marketing budgets of these companies are soaring, there is increasing pressure from the governments all around the world on placing limits on pricing drugs. To large extent, the demand for drugs in developed markets has a strong relation with public health budgets, as healthcare is funded by states. Consequently, rising drug pricing is making governments and non-profit organizations stand up and raise their voice against the excessive pricing policy adopted by drug companies.

    The problems of the Pharma industry do not stop there. Expiring patents and a rush of generic competitors are eating into the profitability of these companies. As patent expires, discoverers are at risk of losing volumes and revenues, as generic competition offers a cheaper alternative. The generic market is expected to approach double-digit growth over the next three years, compared to a mere 5% growth expected for branded formulations.

    The most recent examples of generic threat to these companies are the patent challenge on Augmentin (antibiotic) and Norvasc (Cardiovascular) of Glaxo and Pfizer respectively. These are multi-billion dollar and strategically important patents for multinationals. Augmentin for example contributes to more than 8% of GSK's worldwide revenues. Domestic generic companies, Dr. Reddy's and Ranbaxy, are aggressively challenging the patents for these drugs. As the pharma industry tides through uncertain times, the solution seems to be in a new round of consolidation. Successful mergers to a large extent would help these companies introduce newer molecules to fuel growth and squeezing their marketing costs. Bigger companies with more products have more bargaining power with states and insurance companies, which to a large extent dictate pharmaceutical sales in the US.

    The Pfizer deal to acquire Pharmacia has already kicked in another round of consolidation in the industry. More deals are likely to follow soon. The principal argument for striking merger deals is the cost cutting and leveraging of sales force in the short term, while waiting for new therapies to make their way out of their labs. However, it needs to be seen how successful can these mergers be in the long run, which are right now driven by dry spells in global pharma R&D labs.

     

     

    Equitymaster requests your view! Post a comment on "Global Pharma: Consolidation imminent...". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE HEALTHCARE


    Aug 17, 2017 (Close)

    S&P BSE HEALTHCARE 5-YR ANALYSIS

    COMPARE COMPANY

    MARKET STATS